Effect of the farnesyl transferase inhibitor L-744,832 on the colon cancer cell line DLD-1 and its combined use with radiation and 5-FU

Chemotherapy

Volumn 51, Issue 6, 2005, Pages 319-323

  Kavgaci, Halil ^a   Özdemir, Feyyaz ^a   Ovali, Ercüment ^a   Yavuz, Aydin ^a   Yavuz, Melek ^a   Aydin, Fazil ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

5 Fluorouracil; Farnesyl transferase inhibitor; L 744,832; Radiation resistance

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; DNA; FLUOROURACIL; ISOPROTEIN; MYC PROTEIN; PROTEIN C MYB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN FOS; PROTEIN P53; PROTEIN SIS; RAS PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL COUNT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; COLON CARCINOMA; CONTROLLED STUDY; DNA REPAIR; DOSE RESPONSE; DRUG EFFECT; GENE MUTATION; HUMAN; HUMAN CELL; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; RADIATION DOSE; TIME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FARNESYLTRANSTRANSFERASE; FLUOROURACIL; HUMANS; METHIONINE; RADIATION TOLERANCE;

EID: 27544495547     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088954     Document Type: Article

References (37)

1. Hancock JF, Marshall CJ: Posttranslational processing of ras and ras-related proteins; in Lacal JC, McCormick F (eds): The Ras Superfamily of GTPases. Boca Raton, CRC Press, 1993, pp 65-84.
2. Manne V: Role of ras proteins in signal-transduction; in Nell B, Kumar R (eds): The Molecular Basis of Human Cancer. Mount Kisco, Futura, 1993, pp 145-171.
3. Bos JL: ras oncogenes in human cancer: A review. Cancer Res 1989;49:4682-4689.
4. Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 1993;366:643-654.
5. Gibbs JB, Oliff A: The potential of farnesyltransferase inhibitors as cancer chemothera-peutics. Annu Rev Pharmacol Toxicol 1997;137:143-166.
6. V12 proteins to farnesyl transferase inhibitors in Rat1 cells. Proc Natl Acad Sci USA 1996;93:4454-4458.
7. Whyte DB, Kirschmeier P, Hockenberry TN, et al: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997;272:14459-14464.
8. Rowell CA, Kowalczyk JJ, Lewis MD, et al: Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 1997;272:14093-14097.
9. Liu M, Bryant MS, Chen J, et al: Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998;58:4947-4956.
10. Moasser MM, Sepp-Lorenzino L, Kohl NE, et al: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 1998;95:1369-1374.
11. Wang EJ, Johnson WW: The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2. Chemotherapy 2003;49:303-308.
12. Sun J, Qian Y, Hamilton AD, et al: Ras CAAX peptidomimetic FTI-276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 1995;55:4243-4247.
13. Miyake M, Mizutani S, Koide H, Kaziro Y: Unfarnesylated transforming Ras mutant inhibits the Ras-signaling pathway by forming a stable Ras.Raf complex in the cytosol. FEBS Lett 1996;378:15-18.
14. Bernhard EJ, Kao G, Cox AD, et al: The farnesyl transferase inhibitor FTI-277 radiosensitizes H-Ras-transformed rat embryo fibroblasts. Cancer Res 1996;56:1727-1730.
15. McKenna WG, Kenna MC, Endlich B, et al: Synergistic effects of the v-myc oncogene with H-Ras on radioresistance. Cancer Res 1990;50:97-102.
16. Özdemir F, Esen N, Ovali E, et al: Effects of dexamethasone, all-trans retinoic acid, vitamin D(3), and interferon-α on F0 myeloma cells. Chemotherapy 2004;50:190-193.
17. Kohl NE, Omer CA, Conner MW, et al: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995;58:1253-1259.
18. Lobell RB, Omer CA, Abrams MT, et al: Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 2001;61:8758-8768.
19. End DW, Semets G, Todd AV, et al: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001;61:131-137.
20. Di Paolo A, Danesi R, Caputo S, et al: Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells. Br J Cancer 2001;84:1535-1543.
21. Gibbs JB: Ras C-terminal processing enzymes - New drug targets? Cell 1991;65:1-4.
22. Glomset JA, Gelb MH, Farnsworth CC: Prenyl proteins in eukaryotic cells: A new type of membrane anchor. Trends Biochem Sci 1990;15:139-142.
23. Sepp Lorenzino L, Rosen N: A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J Biol Chem 1998;273:20243-20251.
24. Russo P, Malacarne D, Falugi C, Trombino S, O'Connor PM: RPR-115135, a farnesyltransferase inhibitor, increases 5-FU-cytotoxicity in ten human colon cancer lines: Role of p53. Int J Cancer 2002;100:266-275.
25. Greco C, Alvino S, Buglioni S, et al: Activation of c-myc and c-myb proto-oncogenes is associated with decreased apoptosis in tumor colon progression. Anticancer Res 2001;21:3185-3192.
26. Yi HK, Nam SY, Kim JC, Kim JS, Lee DY, Hwang PH: Induction of apoptosis in K562 cells by dominanat negative c-myb. Exp Hematol 2002;30:1139-1144.
27. Lebowitz PF, Sakamuro D, Prendergast GC: Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res 1997;57:708-713.
28. Adjei AA, Davis JN, Bruzek LM, et al: Synergy of the farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 2001;7:1438-1445.
29. Kuranaga N, Shinomiya N, Mochizuki H: Long-term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: An in vitro study. BMC Cancer 2001;1:10-18.
30. Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suziki N, Fukushima M: Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Cancer 2000;17:277-283.
31. Tokunaga E, Oda S, Fukushima M, Maehra Y, Sugimachi K: Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines. Eur J Cancer 2000;36:1998-2006.
32. Krause K, Wasner M, Reinhard W, et al: The tumor suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res 2000;28:4410-4418.
33. Fitzgerald TJ, Daugherty C, Kase K, Rothstein LA, McKenna M, Greenberger JS: Activated human N-ras oncogene enhances x-irradiation repair of mammalian cells in vitro less effectively at low dose rate. Implications for increased therapeutic ratio of low dose rate irradiation. Am J Clin Oncol 1985;8:517-522.
34. Bernhard EJ, Stanbridge EJ, Gupta S, et al: Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 2000;60:6597-6600.
35. Megnin-Chanet F, Lavelle F, Favaudon V: The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution. BMC Pharmacol 2002;2:2.
36. Bernhard EJ, McKenna WG, Hamilton AD, et al: Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 1998;58:1754-1761.
37. Cohen-Jonathan E, Muschel RJ, McKenna GW, et al: Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res 2000;154:125-132.